Combination treatment in advanced urothelial carcinoma

Affiliations

Comment

Rebecca Tregunna. Nat Rev Urol. 2021 Jul.

. 2021 Jul;18(7):383.

doi: 10.1038/s41585-021-00489-7.

No abstract available

Comment on

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer.
Powles T, Carroll D, Chowdhury S, Gravis G, Joly F, Carles J, Fléchon A, Maroto P, Petrylak D, Rolland F, Cook N, Balar AV, Sridhar SS, Galsky MD, Grivas P, Ravaud A, Jones R, Cosaert J, Hodgson D, Kozarewa I, Mather R, McEwen R, Mercier F, Landers D. Powles T, et al. Nat Med. 2021 May;27(5):793-801. doi: 10.1038/s41591-021-01317-6. Epub 2021 May 3. Nat Med. 2021. PMID: 33941921 Clinical Trial.

1. Powles, T. et al. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat. Med. 27, 793–801 (2021) - DOI